The virus proved it doesn't need a direct flight to move.
In the wake of the WHO's declaration of mpox as a global health emergency, India has moved swiftly and deliberately — not in panic, but in the measured tradition of a nation that has learned, through repeated encounters with infectious disease, that early vigilance is the quietest form of courage. With over 1,100 deaths recorded globally since January 2023 and a new strain breaching Africa's borders for the first time, India is tightening its watch at ports and airports while drawing on an unexpected inheritance: the cross-protective immunity carried by millions who received smallpox and chickenpox vaccines in earlier decades. The country stands at a familiar threshold — aware of the world's fragility, yet grounded in its own preparedness.
- The WHO's August 15 emergency declaration triggered immediate action in India, with high-level government meetings convened within 48 hours to assess and sharpen the country's defenses.
- A new mpox strain crossing from Africa into Sweden — and three cases surfacing in neighboring Pakistan — has raised the stakes for a region that cannot afford complacency.
- Airports and seaports are now under heightened surveillance, with thermal screenings, travel history checks, and special alerts for cities hosting large African student populations like Hyderabad and New Delhi.
- India's existing vaccine infrastructure — smallpox and chickenpox immunization programs — offers a quiet but significant layer of cross-protective immunity that many other nations lack.
- Scientists and health officials are urging calm: India has recorded no new mpox cases since March 2024, and the apparatus is described as alert but not alarmed.
When the WHO declared mpox a global health emergency on August 15, India did not wait. Within two days, senior health officials were convening emergency sessions, with Union Health Minister Jagat Prakash Nadda set to lead a critical review alongside the National Centre for Disease Control and the Indian Council of Medical Research.
India's history with mpox stretches back to 2022, when the virus arrived in Kerala via a traveler from the UAE. That year brought 27 confirmed cases and one death; by mid-2023, the count had reached 31, concentrated in Kerala and Delhi. The last recorded case was in March 2024 — and since then, silence, even as mpox has spread across more than 100 countries and claimed over 1,100 lives globally, with children in Africa bearing the heaviest toll.
What has sharpened India's concern now is the virus's geographic reach. A new strain has appeared in Sweden — the first confirmed spread beyond Africa — while three cases have emerged in Pakistan's Khyber-Pakhtunkhwa province. Tamil Nadu has placed airports and ports on alert, with particular scrutiny on travelers from the Democratic Republic of Congo and Central Africa. Cities with large African student communities, including Hyderabad and New Delhi, have been flagged for heightened monitoring.
Behind the visible screening operations, the Indian Council of Medical Research has been quietly conducting a serosurvey among high-risk populations to map the country's underlying vulnerability. Meanwhile, India holds a structural advantage that many nations do not: millions of its citizens carry cross-protective immunity from smallpox and chickenpox vaccinations, and the Serum Institute of India is already developing a dedicated mpox vaccine.
Experts have been clear — the immediate risk to India remains low, and panic is unwarranted. The new strain circulating in eastern Congo has not reached Indian shores. What India has assembled is not alarm, but readiness: a posture shaped by experience, sustained by surveillance, and anchored in the knowledge that preparation is its own form of protection.
The World Health Organization's declaration of mpox as a global health emergency on August 15 sent India into motion within hours. Two days later, the country's health apparatus was already convening high-level meetings and drafting fresh protocols to intercept the virus before it could gain a foothold. Union Health Minister Jagat Prakash Nadda was scheduled to lead a critical session with officials from the National Centre for Disease Control and the Indian Council of Medical Research to assess vulnerabilities and sharpen defenses.
India's encounter with mpox is not new. The virus arrived in Kerala in 2022, carried by a traveler from the United Arab Emirates. What followed was a contained but notable outbreak: 27 confirmed cases and one death across the country that year, with cases spreading to Delhi among people with no recent international travel history. By mid-2023, the count had climbed to 31 cases, concentrated in Kerala and Delhi. The last documented infection in India occurred in March 2024, also in Kerala. Since then, the country has recorded no new cases, even as the virus has surged across more than 100 countries globally.
The current global situation carries weight that India cannot ignore. Since January 2023, mpox has infected roughly 27,000 people worldwide and killed more than 1,100, with children bearing a disproportionate burden in African nations. In August, health officials confirmed a new strain had crossed into Sweden, marking the first time the virus had spread beyond Africa. The European Centre for Disease Prevention and Control elevated its risk assessment from low to moderate. Adding to India's concern, three cases have appeared in Pakistan's Khyber-Pakhtunkhwa province, which shares a border with Afghanistan.
Yet India's response reflects both urgency and measured assessment. Tamil Nadu's health directorate has heightened vigilance at airports and ports, with particular attention to passengers arriving from the Democratic Republic of Congo and Central African nations. Hyderabad and New Delhi, cities that attract substantial numbers of African students, have been placed on alert. Health officers in major Tamil Nadu cities have been instructed to recognize mpox symptoms, conduct thermal screenings, and verify travel histories from the past three weeks. The health ministry plans to issue formal advisories to all major entry points—airports, seaports—to ensure suspected cases are identified and managed swiftly.
Behind the scenes, the Indian Council of Medical Research has been conducting a serosurvey since last year to gauge mpox exposure among high-risk populations, building a baseline understanding of vulnerability across the country. This intelligence gathering complements the visible screening operations.
One significant advantage India possesses is existing vaccine coverage. While no vaccine specifically targets mpox, the smallpox and chickenpox vaccines already administered to millions of Indians offer cross-protective immunity. The immune system recognizes structural similarities between these viruses and mounts a defense. Children in India receive the varicella vaccine against chickenpox between 12 and 15 months, with a booster between ages four and six. Anyone over 44 who received smallpox vaccination in childhood carries immunity to mpox as well. This existing shield, combined with India's formidable vaccine manufacturing capacity, positions the country differently than many nations facing the outbreak. The Serum Institute of India is already developing an mpox vaccine, and there have been calls for other pharmaceutical companies and diagnostic manufacturers to accelerate development of testing kits.
Experts emphasize that despite the global emergency, India's immediate risk remains low. Scientists at the National Institute of Virology in Pune and other health officials have stated plainly that panic is unwarranted. The new strain circulating in eastern Congo has not yet appeared in India. Surveillance systems are active, advisories are in place, and monitoring of international trends continues. The apparatus is alert but not alarmed—a posture that reflects both the genuine threat the virus poses globally and the specific protections and preparedness India has already assembled.
Citas Notables
The current upsurge of mpox in parts of Africa, along with the spread of a new sexually transmissible strain of the virus, is an emergency, not only for Africa but for the entire globe.— Professor Dimie Ogoina, Chair of the IHR Emergency Committee
At the moment, the risk of a surge in monkeypox infection is very low in India, and there is no need to panic.— Health ministry source
La Conversación del Hearth Otra perspectiva de la historia
Why did India move so quickly after the WHO declaration when the country hasn't seen a case in five months?
Because mpox has shown it can travel. It arrived in Kerala from the UAE in 2022, then spread to Delhi among people with no international travel. The virus proved it doesn't need a direct flight to move. When you see it surging across 100 countries and a new strain reaches Europe, you don't wait to see if it reaches your borders.
What's the actual risk to India right now?
Low, by all accounts. No cases since March. But low isn't zero, especially when you have three cases next door in Pakistan and major cities full of students from affected regions. The screening at airports isn't theater—it's the difference between catching one case at arrival and having it seed a cluster.
The vaccine situation seems like India's real advantage here.
It is. Most Indians over 44 got smallpox vaccine as children. Younger people got chickenpox vaccine. Both viruses are related enough that the immune system recognizes mpox. It's not perfect protection, but it's something most countries don't have. And India manufactures vaccines at scale—if they need to produce mpox vaccines, they can.
Why focus screening on African students in Hyderabad and Delhi?
Because that's where the virus is circulating most heavily right now, and those cities have the largest populations of people traveling to and from those regions. It's epidemiology, not prejudice. You screen where the risk is highest.
What happens if a case does appear?
The protocols are already written. Isolation, contact tracing, thermal screening at entry points, travel history verification. India did this in 2022 and contained it to 27 cases. The machinery exists. The question is whether it moves fast enough if the virus does arrive.